Welcome to our dedicated page for Neuropace SEC filings (Ticker: NPCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeuroPace, Inc. (Nasdaq: NPCE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed medical device company focused on epilepsy treatment through its brain-responsive RNS System, NeuroPace uses SEC filings to report financial performance, material events, and corporate governance changes.
Investors can use this page to locate NeuroPace’s periodic reports and current reports on Form 8-K. Recent 8-K filings have furnished press releases announcing quarterly financial results, including revenue growth driven primarily by RNS System sales, gross margin performance, and updated annual guidance. Other 8-K filings have described material events such as executive transitions in the chief financial officer role, associated separation and employment agreements, and related compensation and equity award terms.
Through its SEC filings, NeuroPace also discloses information on its capital structure, long-term debt, cash and short-term investments, and operating expenses across sales and marketing, research and development, and general and administrative functions. These documents provide detail that complements the company’s public news releases, including condensed balance sheets, statements of operations, and cash flow information.
On Stock Titan, users can review NeuroPace’s filings as they are made available from the SEC’s EDGAR system and use AI-powered summaries to interpret complex disclosures. AI-generated overviews can help explain key points from lengthy filings, such as financial trends, major risk factor themes, and the implications of material events described in Form 8-Ks. Users can also track items related to executive compensation arrangements, severance benefits, equity awards, and officer appointments as described in governance-related filings.
For those analyzing NPCE, this filings page offers a structured view into how NeuroPace reports its operations, finances, and leadership changes over time. By combining real-time EDGAR updates with AI summaries, the page helps readers understand the regulatory record behind NeuroPace’s RNS System-focused business, its neuromodulation and AI development programs, and its ongoing engagement with investors and regulators.
NeuroPace, Inc. (NPCE) – Form 3 Initial Statement of Beneficial Ownership
Chief Financial Officer Patrick F. Williams filed an initial Form 3 for an event dated 06/20/2025. The document confirms that he currently holds no beneficial ownership—neither common stock nor derivative securities—in NeuroPace. The filing was signed by attorney-in-fact Leah Akin on 06/24/2025.
Form 3 is required when an individual becomes a Section 16 insider (director, officer, or >10 % shareholder). This submission fulfills that requirement and sets Williams’s baseline ownership level for future insider transaction reporting.
On 24 June 2025, NeuroPace (NPCE) filed a Form 4 for director Dr. Uri Geiger detailing a series of stock grants received as part of the company’s non-employee director compensation policy, issued in lieu of cash retainers.
- Latest grant: 1,140 shares on 21 June 2025 at $10.41.
- Cumulative direct holdings: 12,036 common shares after the reported transactions.
- Grant history: Eight quarterly issuances from 30 June 2023 through 21 June 2025, priced between $4.49 and $13.20, all coded “A” (acquisition).
- Indirect holdings: 4,432,948 shares held through Accelmed Partners II LP, over which Dr. Geiger exercises sole voting and dispositive control.
No shares were sold, and there are no derivative security movements disclosed. The filing is administrative, reflecting routine equity compensation rather than a strategic insider transaction.
NeuroPace director Rakhi Kumar reported multiple acquisitions of common stock between June 2023 and June 2025, received as compensation under the company's non-employee director compensation policy in lieu of quarterly retainer fees.
Key transaction details:
- Total shares accumulated: 15,594 shares
- Purchase prices ranged from $4.49 to $13.20 per share
- Largest single acquisition: 3,340 shares on June 30, 2023
- Most recent acquisition: 1,440 shares at $10.41 on June 21, 2025
All transactions were direct acquisitions, with shares held in direct ownership. The consistent pattern of quarterly acquisitions suggests regular board compensation practices, with share quantities varying based on the prevailing stock price at each grant date.
Joseph Lacob, Director at NeuroPace, reported multiple acquisitions of common stock through the company's non-employee director compensation policy in lieu of quarterly retainer fees from June 2023 to June 2025.
Key transactions include:
- Nine separate acquisitions totaling 11,696 shares at prices ranging from $4.49 to $13.20
- Most recent acquisition: 1,080 shares at $10.41 on June 21, 2025
- Current direct ownership: 12,080 shares
- Significant indirect ownership through: - Lacob Ventures LLC: 128,174 shares - LCT18 Investments: 223,554 shares
Total beneficial ownership (direct and indirect) amounts to 363,808 shares, demonstrating substantial insider stake in the company. All direct acquisitions were made as compensation for board service rather than open market purchases.
NeuroPace director Frank M. Fischer reported multiple acquisitions of common stock through the company's non-employee director compensation policy in lieu of quarterly retainer fees from June 2023 to June 2025. Key transactions include:
- Most recent acquisition: 2,281 shares at $10.41 per share on June 21, 2025
- Largest acquisition: 4,469 shares at $4.49 per share on June 30, 2023
- Total shares accumulated: Increased position from 570,126 to 589,531 shares
- Share price range: $4.49 to $13.20 across nine quarterly acquisitions
All transactions were direct ownership acquisitions, with no derivative securities involved. The consistent pattern of stock acquisitions in lieu of cash compensation demonstrates the director's long-term alignment with shareholder interests and confidence in the company's future.